( Preliminary results from a large rando...)Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer

Preliminary results from a large, randomized clinical trial for patients with previously untreated recurrent or metastatic breast cancer ?cancer that has spread from the breast to other parts of the body ?show that those patients who received bevacizumab (Avastin? in combination with standard chemotherapy had a longer time period before their cancer progressed than patients who received the same chemotherapy without bevacizumab.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). Genentech, Inc., South San Francisco, Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.

The Data Monitoring Committee overseeing the trial (known as E2100)* recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of increasing progression-free survival (the amount of time patients lived without the cancer getting worse).

Preliminary results suggest that patients in the study who received bevacizumab in combination with standard chemotherapy consisting of single-agent paclitaxel had a delay in worsening of their cancer by four months, on average, compared to patients treated with paclitaxel chemotherapy alone. This difference is statistically significant.
“This study is the first to find a benefit of anti-angiogenic therapy in patients with breast cancer and represents a major advance in the treatment of patients with metastatic disease," said Study Chair Kathy D. Miller, M.D., of the Indiana University Medical Center in Indianapolis, Ind. Anti-angiogenic drugs, also called angiogenesis inhibitors, are substances that may prevent angiogenesis, or the formation of blood vessels. In anticancer therapy, a
'"/>

Source:NIH

Page: 1 2 3
Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Combined treatment extends life expectancy for lung cancer patients
3. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
4. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
5. Chemotherapy gel may fight breast cancer and reduce breast deformity
6. Chemotherapy temporarily affects the structures of the human brain
7. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
8. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
9. Survival of heart patients on beta-blockers varies greatly with genetic variation
10. Survival of the selfless - scientists find cheats dont always prosper
11. Survival of the rarest: Fruit flies shed light on the evolution of behavior